Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan vs Enalapril in HFrEF With Moderate Renal Impairment (TRIUMF)
NCT04736329Completed
- Sponsor
- Cairo University
- Start
- Feb 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of telmisartan in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Cairo University. Primary endpoints: Six-Minute Walk Test at 6 months, Worsening Renal Function at 2 months and 1 more. Started Feb 2021; status: completed.
02
Drugs
telmisartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT04736329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736329.